Abstract
Considerable studies exploring the relevance of single-nucleotide polymorphisms (SNPs) in the prostate cancer noncoding RNA 1 (PRNCR1) gene with various cancer susceptibilities have obtained debatable results. This meta-analysis was performed to precisely assess this association. Relevant published studies were selected by retrieving studies from PubMed, Embase, Web of Science, CNKI and Chinese Wanfang databases. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were applied to evaluate the strength of PRNCR1 polymorphisms correlated with cancer susceptibility. A total of 12 articles, containing 40 independent case–control studies and seven SNPs (rs1016343, rs13252298, rs16901946, rs7007694, rs1456315, rs13254738 and rs7463708), were ultimately included in our meta-analysis. Summary results revealed a significant association with an increased overall risk of cancer for the rs1016343 C>T polymorphism (T vs C: OR=1.19, 95% CI=1.02–1.39; TT+CT vs CC: OR= 1.25, 95% CI=1.05–1.49) and rs16901946 A>G polymorphism (G vs A: OR=1.17, 95% CI=1.09–1.27; GG+AG vs AA: OR=1.20, 95% CI=1.09–1.32). Moreover, evidence of the rs13252298 A>G polymorphism correlation with decreased overall risk of cancer was observed (GG vs AG+AA: OR=0.78, 95% CI =0.67–0.92). Subgroup analyses by cancer type and ethnicity also revealed that the rs1016343 C>T polymorphism was linked with an increased risk of prostate cancer and Caucasians, respectively. The rs13252298 A>G polymorphism was correlated with a decreased risk of colorectal cancer and prostate cancer. The rs16901946 A>G polymorphism was related to an increased risk of gastric cancer and colorectal cancer in Asians. Additionally, the rs13254738 A>C polymorphism was correlated with reduced cancer risk in Asians. No correlations were discovered with cancer risk in rs7007694 T>C, rs7463708 T>G, and rs1456315 A>G polymorphisms. In summary, our meta-analysis indicates that PRNCR1 rs1016343, rs16901946 and 13252298 polymorphisms are associated with cancer susceptibility. Further large-scale studies are required to certify our findings.
Similar content being viewed by others
References
AlMutairi M., Parine N. R., Shaik J. P., Aldhaian S., Azzam N. A., Aljebreen A. M. et al. 2019 Association between polymorphisms in PRNCR1 and risk of colorectal cancer in the Saudi population. PLoS One 14, e0220931.
Cheetham S. W., Gruhl F., Mattick J. S. and Dinger M. E. 2013 Long noncoding RNAs and the genetics of cancer. Br. J. Cancer 108, 2419–2425.
Cheng D., Bao C., Zhang X., Lin X., Huang H. and Zhao L. 2018 LncRNA PRNCR1 interacts with HEY2 to abolish miR-448-mediated growth inhibition in non-small cell lung cancer. Biomed. Pharmacother. 107, 1540–1547.
Chu H., Chen Y., Yuan Q., Hua Q., Zhang X., Wang M. et al. 2017 The HOTAIR, PRNCR1 and POLR2E polymorphisms are associated with cancer risk: a meta-analysis. Oncotarget 8, 43271–43283.
Chung S., Nakagawa H., Uemura M., Piao L., Ashikawa K., Hosono N. et al. 2011 Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 102, 245–252.
Do H. and Kim W. 2018 Roles of oncogenic long non-coding RNAs in cancer development. Genomics Inform. 16, e18.
Dong L. M., Potter J. D., White E., Ulrich C. M., Cardon L. R. and Peters U. 2008 Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 299, 2423–2436.
Fatica A. and Bozzoni I. 2014 Long non-coding RNAs: new players in cell differentiation and development. Nat. Rev. Genet. 15, 7–21.
Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D. M., Pineros M. et al. 2019 Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941–1953.
Guo Q., Lv S., Wang B., Li Y., Cha N., Zhao R. et al. 2019 Long non-coding RNA PRNCR1 has an oncogenic role in breast cancer. Exp. Ther. Med. 18, 4547–4554.
Guttman M. and Rinn J. L. 2012 Modular regulatory principles of large non-coding RNAs. Nature 482, 339–346.
He B. S., Sun H. L., Xu T., Pan Y. Q., Lin K., Gao T. Y. et al. 2017 Association of genetic polymorphisms in the LncRNAs with gastric cancer risk in a Chinese population. J. Cancer 8, 531–536.
Heemers H. V. and Tindall D. J. 2007 Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 28, 778–808.
Hong J. H., Jin E. H., Kang H., Chang I. A., Lee S. I. and Sung J. K. 2019 Correlations between genetic polymorphisms in long non-coding RNA PRNCR1 and gastric cancer risk in a Korean population. Int. J. Mol. Sci. 20.
Huang X., Zhang W. and Shao Z. 2018 Association between long non-coding RNA polymorphisms and cancer risk: a meta-analysis. Biosci. Rep. 38.
Hui J., Xu Y., Yang K., Liu M., Wei D., Wei D. et al. 2014 Study of genetic variants of 8q21 and 8q24 associated with prostate cancer in Jing-Jin residents in northern China. Clin. Lab. 60, 645–652.
Khawar M. B., Abbasi M. H. and Sheikh N. 2016 IL-32: A novel pluripotent inflammatory interleukin, towards gastric inflammation, gastric cancer, and chronic rhino sinusitis. Mediators Inflamm. 2016, 8413768.
Li L., Jia F., Bai P., Liang Y., Sun R., Yuan F. et al. 2016 Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of gastric cancer. Tumour Biol. 37, 299–303.
Li L., Sun R., Liang Y., Pan X., Li Z., Bai P. et al. 2013 Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of colorectal cancer. J. Exp. Clin. Cancer Res. 32, 104.
Lv Z., Xu Q. and Yuan Y. 2017 A systematic review and meta-analysis of the association between long non-coding RNA polymorphisms and cancer risk. Mutat. Res. 771, 1–14.
Mantel N. and Haenszel W. 1959 Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22, 719–748.
Mercer T. R., Dinger M. E. and Mattick J. S. 2009 Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 10, 155–159.
Oremus M., Oremus C., Hall G. B. and McKinnon M. C. 2012 Inter-rater and test-retest reliability of quality assessments by novice student raters using the Jadad and Newcastle-Ottawa Scales. BMJ Open. 2.
Ponder B. A. 2001 Cancer genetics. Nature 411, 336–341.
Qin Z., Li X., Tang J., Jiang X., Yu Y., Wang C. et al. 2016 Association between insulin-like growth factor-binding protein-3 polymorphism-202 A/C and the risk of prostate cancer: a meta-analysis. Onco. Targets Ther. 9, 5451–5459.
Romani M., Pistillo M. P. and Banelli B. 2015 Environmental epigenetics: crossroad between public health, lifestyle, and cancer prevention. Biomed. Res. Int. 2015, 587983.
Salinas C. A., Kwon E., Carlson C. S., Koopmeiners J. S., Feng Z., Karyadi D. M. et al. 2008 Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 17, 1203–1213.
Sattarifard H., Hashemi M., Hassanzarei S., Narouie B. and Bahari G. 2017 Association between genetic polymorphisms of long non-coding RNA PRNCR1 and prostate cancer risk in a sample of the Iranian population. Mol. Clin. Oncol. 7, 1152–1158.
Tian Y., Wan H., Lin Y., Xie X., Li Z. and Tan G. 2013 Androgen receptor may be responsible for gender disparity in gastric cancer. Med. Hypotheses 80, 672–674.
Uszczynska-Ratajczak B., Lagarde J., Frankish A., Guigo R. and Johnson R. 2018 Towards a complete map of the human long non-coding RNA transcriptome. Nat. Rev. Genet. 19, 535–548.
Wang C. C. and Palefsky J. M. 2016 Human papillomavirus-related oropharyngeal cancer in the HIV-infected population. Oral Dis. 22 (Suppl 1), 98–106.
Wang X., Zhong J., Chen F., Hu K., Sun S., Leng Y. et al. 2019 Association between lncRNA H19 rs217727 polymorphism and the risk of cancer: an updated meta-analysis. BMC Med. Genet. 20, 186.
Yang L., Lin C., Jin C., Yang J. C., Tanasa B., Li W. et al. 2013 lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 500, 598–602.
Yang L., Qiu M., Xu Y., Wang J., Zheng Y., Li M. et al. 2016 Upregulation of long non-coding RNA PRNCR1 in colorectal cancer promotes cell proliferation and cell cycle progression. Oncol. Rep. 35, 318–324.
Yang M. L., Huang Z., Wu L. N., Wu R., Ding H. X. and Wang B. G. 2019 lncRNA-PCAT1 rs2632159 polymorphism could be a biomarker for colorectal cancer susceptibility. Biosci. Rep. 39.
Yang X. B., Wang J. S., Zhou J. and Pan C. 2018 Association of genetic variations of LncRNA PRNCR1 and risk of gastric cancer. Acta Univ. Med. Nanjing 38, 1520–1524.
Zheng S. L., Hsing A. W., Sun J., Chu L. W., Yu K., Li G. et al. 2010 Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. Prostate 70, 425–432.
Zhou H. C., Huang K., Chen X. L., Ren M. and Liu J. R. 2019 The relationship between polymorphism of LncRNA-PRNCR1 and susceptibility and prognosis of intestinal cancer. Med. Innov. China 16, 66–69.
Acknowledgments
We thank Luping Wang for providing help in data analysis.
Author information
Authors and Affiliations
Corresponding author
Additional information
Corresponding editor: Upendra Nongthomba
Rights and permissions
About this article
Cite this article
Du, P., Li, G., Zhu, J. et al. Association of lncRNA PRNCR1 polymorphisms with cancer susceptibility: a meta-analysis of the current literature. J Genet 100, 19 (2021). https://doi.org/10.1007/s12041-021-01269-3
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12041-021-01269-3